Most of the chemotherapeutic agents available for clinical practice have been employed against prostatic cancer, either alone or in combination. Evaluation of the results has been complicated by various factors, not the least of which relates to the nature of the disease itself. In this comprehensive review of the literature, the authors have compiled the results to date.